CJC-1295 (no DAC)

CJC-1295 is structurally similar to endogenous GHRH but has been modified to increase its half-life and bioavailability. Research indicates that CJC-1295 binds to GHRH receptors on somatotroph cells in the anterior pituitary, activating the cAMP signaling pathway. This activation leads to increased transcription of the GH gene, resulting in enhanced synthesis and secretion of GH.

• Growth Hormone and IGF-1 Levels: Multiple studies have demonstrated that CJC-1295 administration can significantly increase circulating levels of GH and insulin-like growth factor 1 (IGF-1) in animal models. Research in healthy adult males has shown that a single dose of CJC-1295 can lead to sustained elevations in GH and IGF-1 for several days.
• Body Composition: Research in animal models has suggested potential effects on body composition. Studies in rats have found that CJC-1295 administration was associated with increased lean body mass and decreased fat mass.
• Bone Density: Some animal studies have investigated the effects of CJC-1295 on bone metabolism. Research in aged rats has reported improvements in bone mineral density following CJC-1295 treatment.
• Immune Function: Limited research has explored the potential immunomodulatory effects of CJC-1295. Studies in mice have observed alterations in certain immune parameters following CJC-1295 administration, though more research is needed to fully understand these effects.

While the aforementioned studies did not report severe adverse effects, it’s important to note that long-term safety data in is limited. Potential side effects associated with elevated GH levels may include fluid retention, joint discomfort, and alterations in glucose metabolism, though these have not been extensively studied in the context of CJC-1295 specifically.

CJC-1295 is a research peptide that has demonstrated the ability to stimulate GH and IGF-1 secretion in animal studies. While initial research suggests potential effects on body composition, bone density, and immune function, further studies are needed to fully elucidate its physiological impacts and safety profile. As with any experimental compound, CJC-1295 should be approached with caution and studied under appropriate research protocols.

1. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.
2. Sackmann-Sala, L., Ding, J., Frohman, L. A., & Kopchick, J. J. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research, 19(6), 471-477.
3. Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797.
4. Corpas, E., Harman, S. M., & Blackman, M. R. (1993). Human growth hormone and human aging. Endocrine Reviews, 14(1), 20-39.
5. Veldhuis, J. D., Patrie, J. T., Frick, K., Weltman, J. Y., & Weltman, A. (2005). Sustained growth hormone (GH) and insulin-like growth factor I responses to prolonged high-dose twice-daily GH-releasing hormone stimulation in middle-aged and older men. The Journal of Clinical Endocrinology & Metabolism, 90(6), 3604-3610.